Iqymune (Human Normal Immunoglobulin)

Human Normal Immunoglobulin provides a broad spectrum of IgG antibodies derived from pooled donor plasma. These antibodies bind to pathogens, neutralize toxins, and opsonize microbes, thereby compensating for the patient’s insufficient antibody production and enhancing overall immune defense.

The dosage of Iqymune is individualized. A qualified prescriber determines the amount and infusion rate based on the patient’s IgG trough level, body weight, clinical response, and other relevant factors. No standard dose is provided here.

Safety data for Iqymune in pregnancy and lactation are limited, and the product is classified as pregnancy category unknown. It should be used only if the potential benefit justifies any potential risk, and decisions must be made by the treating physician.

Submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details and necessary import documentation.

Iqymune contains pooled human IgG similar to other IVIG preparations, offering comparable efficacy in immunoglobulin replacement. Differences may exist in manufacturing processes, stabilizers, and regulatory approvals, which can influence tolerability, permissible infusion rates, and supply logistics.

Iqymune must be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. Before administration, allow the solution to reach room temperature if required, and inspect the vial for any particulate matter or discoloration.

Iqymune is given as an intravenous infusion. The infusion rate is gradually increased under medical supervision, with vital signs monitored throughout the procedure. Premedication may be used to reduce the likelihood of infusion‑related reactions.

Serious adverse events include anaphylaxis, thromboembolic complications, acute renal failure, aseptic meningitis, severe hemolysis, and profound thrombocytopenia. Immediate medical attention is required if any of these symptoms occur during or after the infusion.

Iqymune is contraindicated in patients with known severe IgA deficiency who have anti‑IgA antibodies, and in individuals with a history of severe hypersensitivity to immunoglobulin products. Caution is also advised for patients with uncontrolled hypercoagulable disorders.